Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis?

Mar 13 18:03 2018 Print This Article

A: Johnson & Johnson, $135.11, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $364.8 billion; www.jnj.com), operates through three major businesses: Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs; Medical devices and diagnostics (35%) sells equipment for joint reconstruction and managing circulatory diseases; Consumer (18%) makes over-the-counter products […]

The post Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis? appeared first on TSI Wealth Network.

Read More

About Article Author

TSI Network Daily

TSI Network is the online home of Pat McKeough’s highly successful family of investment publications, TSI The Successful Investor, TSI Stock Pickers Digest, TSI Wall Street Stock Forecaster and TSI Canadian Wealth Advisor. While most media outlets only cover the popular investment theories of the day, TSI Network goes beyond the headlines to get to the heart of what really affects you – the individual investor. The site is based on Pat’s rock-solid investing system and his unflinching focus on helping North American investors make the right choices for their own unique investment needs. A professional investment analyst for more than 25 years, Pat has developed a stock-selection technique that has proven reliable in both bull and bear markets. His proprietary ValuVesting System™ focuses on stocks that provide exceptional quality at relatively low prices. Many savvy investors and industry leaders consider it the most powerful stock-picking method ever createdAs early as 1980, Pat was recognized as #1 in the world of published investment advice by the Washington, DC–based Newsletter Publishers Association, and he was the first multi-year winner of The Globe and Mail‘s stock picking contest. Both CBS MarketWatch and The Hulbert Financial Digest recognize Pat as one of North America’s top stock analysts. The Wall Street Journal calls him “one of only four investment newsletter advisors who have managed to serve their readers well over the long haul.”

  Categories:

Related Items

Capital Constellation Backs Ara Partners Group With $150 Million

Capital Constellation said July 16 it closed a $150 million strategic partnership with Ara Partners Group and acquired a substantial minority ownership interest in the energy-focused private-equity firm based in Houston. As a result, Capital Constellation, a New York-based joint venture (JV), will p ...

More isn’t better

Netflix is crashing today after last night’s news that subscriber adds were not as many as Wall Street had been expecting. Netflix rarely misses this number, but it has happened before. The stock is prone to massive rallies and selloffs, given revolutionary nature of what they’ve built and the i ...

Q&A: Pierre Bechelany Guides Fluor’s Pipeline, LNG Growth

Pierre Bechelany left Louisiana Tech University with two degrees in mechanical engineering and a job with GE working on a contract for NASA. It turned out that space would be his first but not final frontier. Six weeks into his career, Bechelany received a call from Bechtel with an offer for a job i ...

EMA.PR.C To Reset At 4.721%

Emera Incorporated has announced: the applicable dividend rates for its Cumulative Rate Reset First Preferred Shares, Series C (the “Series C Shares”) and Cumulative Floating Rate First Preferred Shares, Series D (the “Series D Shares”), in each case, payable if, as and when declared by the ...

Canopy Growth Corp CEO Linton says the price of marijuana is not important to him

Bruce Linton (left) with Jim Cramer No one can fault Canopy Growth’s (TSX:WEED, NYSE:CGC) Bruce Linton for not dreaming big. Even with Canada’s recreational cannabis market about to open in a few short months, the CEO of the world’s largest marijuana company is already thinking beyond dried ...

Which pharmaceutical drugs have the most drug patents in Portugal?

This chart shows the drugs with the most patents in Portugal. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Portugal? appeared first on DrugPatentWatch - Make B ...

New patent for Hq Spclt drug DEXMEDETOMIDINE HYDROCHLORIDE

Annual Drug Patent Expirations for DEXMEDETOMIDINE+HYDROCHLORIDE Dexmedetomidine Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Inc, Akorn Inc, Aurobindo Pharma Ltd, Fresenius Kabi Usa, Jiangsu Hengrui Med, Luitpold Pharms… The post New patent for Hq Spclt drug DEXMEDETOMIDINE HYDROC ...

Which pharmaceutical drugs have the most drug patents in United Kingdom?

This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical drugs have the most drug patents in United Kingdom? appeared first on DrugPatentWatch - Mak ...